title: Expression of Fas ligand in patients with evident skull base involvement of nasopharyngeal carcinoma.
abstract: We investigated whether skull base involvement in patients with nasopharyngeal carcinoma (NPC) is correlated with expression of Fas ligand (FasL) in NPC cells. A prospective assessment of FasL expression was determined by immunohistochemistry and in situ hybridization in 98 patients with newly diagnosed NPC. Among these patients, 21 had evident skull base involvement. Expressions of human apoptosis-related genes and FasL were confirmed by reverse transcription-polymerase chain reaction. Relation between the frequency of skull base involvement and FasL expression was analyzed by Chi-square and multivariate analyses. FasL expression was detected in 32 (32.6%) of 98 pathological sections. Compared to patients with low FasL expression in tumors, patients with notable FasL expression had higher incidence of skull base involvement (28.6 vs. 71.4%, p<0.005). Expression of FasL in tumor cells was correlated with the higher frequency of skull base involvement in patients with NPC.
authors.affiliation: Department of Otolaryngology, China Medical College Hospital and Institute of Medical Research, Taichung, Taiwan.
authors.forename: Ming-Hsui
authors.initials: MH
authors.lastname: Tsai
authors.forename: Kuan-Chih
authors.initials: KC
authors.lastname: Chow
authors.forename: Tze-Yi
authors.initials: TY
authors.lastname: Lin
authors.forename: Su-Peng
authors.initials: SP
authors.lastname: Yeh
authors.forename: Chung-Tsen
authors.initials: CT
authors.lastname: Hsueh
authors.forename: Kwan-Hwa
authors.initials: KH
authors.lastname: Chi
mesh_terms: D000328:Adult; D017931:DNA Primers / Q000737:chemistry; D053222:Fas Ligand Protein; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D017403:In Situ Hybridization; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D020559:Monomeric GTP-Binding Proteins / Q000378:metabolism; D054778:NM23 Nucleoside Diphosphate Kinases; D009303:Nasopharyngeal Neoplasms / Q000378:metabolism* / Q000473:pathology; D009367:Neoplasm Staging; D009701:Nucleoside-Diphosphate Kinase; D011446:Prospective Studies; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019292:Skull Base Neoplasms / Q000378:metabolism* / Q000473:pathology; D014157:Transcription Factors / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D019014:fas Receptor / Q000235:genetics / Q000378:metabolism
chemical_list: D017931:DNA Primers; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D054778:NM23 Nucleoside Diphosphate Kinases; D019253:Proto-Oncogene Proteins c-bcl-2; D012333:RNA, Messenger; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53; D019014:fas Receptor; D009701:Nucleoside-Diphosphate Kinase; D020559:Monomeric GTP-Binding Proteins